KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ TẾ BÀO GAN GIAI ĐOẠN TIẾN TRIỂN BẰNG TRUYỀN HÓA CHẤT ĐỘNG MẠCH GAN TẠI BỆNH VIỆN HỮU NGHỊ VIỆT ĐỨC

Abstract

Objectives: To describe the clinical and paraclinical characteristics and evaluate treatment outcomes of hepatic arterial infusion chemotherapy with an implantable port system (HAIC) in patients with advanced hepatocellular carcinoma (HCC). Methods: A retrospective, prospective, descriptive study was conducted on 21 patients diagnosed with advanced HCC at Viet Duc University Hospital from 2023 to 2025. Clinical parameters, tumor size, alpha-fetoprotein (AFP) levels, and treatment response according to modified RECIST (mRECIST) criteria were assessed. Results: Tumor size progressively decreased during the first three months after treatment, with the proportion of tumors < 6cm increasing from 42.9% to 50% and the mean diameter decreasing from 73.4mm to 61.4mm. Serum AFP levels also declined, with patients having AFP < 20 ng/mL rising from 38.1% to 60%, indicating a favorable biological response. According to mRECIST criteria, complete response (CR) rates increased from 10% to 28.6%, while partial response (PR) decreased from 45% to 28.6%; stable disease (SD) remained around 28 - 30%, and progressive disease (PD) slightly decreased, reflecting good early disease control. This trend was maintained in the patients followed up to six months. Conclusion: HAIC demonstrated efficacy in reducing tumor size, improving AFP levels, and achieving favorable treatment response rates in patients with advanced HCC.